What is IVERIC bio Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. IVERIC bio's interest expense for the
three
months ended in Mar. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. IVERIC bio's Operating Income for the
three
months ended in Mar. 2023 was $ -73.84 Mil. IVERIC bio's Interest Expense for the
three
months ended in Mar. 2023 was $ 0.00 Mil.
GuruFocus does not calculate IVERIC bio's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
IVERIC bio Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVERIC bio (NAS:ISEE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
IVERIC bio's Interest Expense for the
three
months ended in Mar. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2023 was $-73.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2023 was $96.99 Mil.
IVERIC bio's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as
| GuruFocus does not calculate IVERIC bio's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. IVERIC bio Inc has enough cash to cover all of its debt. Its financial situation is stable.
IVERIC bio (IVERIC bio) Business Description
Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, New Jersey, USA, 07054
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases, or IRDs.
Executives
| Keith Westby |
officer: SVP & COO |
ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540 |
| David Francis Carroll |
officer: SVP, CFO and Treasurer |
ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540 |
| Glenn Sblendorio |
director |
3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036 |
| Christopher Paul Simms |
officer: Senior Vice President, CCO |
FIVE PENN PLAZA SUITE 2372, NEW YORK NY 10001 |
| Anthony S Gibney |
officer: EVP, Chief Business Officer |
C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
| Calvin W. Roberts |
director |
6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
| Christine Ann Miller |
director |
5 PENN PLAZA, SUITE 2372, NEW YORK NY 10001 |
| Pravin Dugel |
officer: EVP, Chief Strategy & Business |
C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242 |
| David R Guyer |
director, officer: Chief Executive Officer |
ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119 |
| Mark S. Blumenkranz |
director |
C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111 |
| Adrienne L Graves |
director |
125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
| Versant Venture Capital Iv, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Versant Ventures Iv, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Versant Side Fund Iv, L.p. |
10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Jane Henderson |
director |
C/O ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE MA 02142 |
IVERIC bio (IVERIC bio) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ISEE has been successfully added to your 